Study of BH3120 with or without pembrolizumab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new drug, BH3120, that boosts the immune system's ability to fight cancer. It's for people with advanced solid tumors that haven't responded to standard treatments. The drug may be given alone or with another immunotherapy drug called pembrolizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor (not in the brain or central nervous system) that has spread or can't be removed by surgery, and no standard treatment is available.
- Your tumor must test positive for a protein called PD-L1 (score at least 1%).
- You must have at least one measurable tumor that hasn't been treated with radiation.
- You must be an adult (18 or older, or the legal age in your country) and be in generally good health (able to do daily activities).
- You must have adequate liver and blood function.
- You must not have had prior treatment with an anti-4-1BB drug, active brain metastases, another progressing cancer, certain liver diseases, or an autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HM16390, either by itself or combined with pembrolizumab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it can shrink tumors.
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
This trial tests a new drug, BHV-1530, either alone or with another drug called cemiplimab, for people with certain advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it's safe and effective.
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
This trial is testing a new drug called BC3195 combined with pembrolizumab (Keytruda) for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow cancer growth.
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.